IGFBP4 and pulmonary fibrosis: Our findings demonstrate that IGFBP‐4 exerts antifibrotic effects in vitro, ex vivo, and in vivo, and its levels are reduced in primary pulmonary fibroblasts of patients with SSc‐associated pulmonary fibrosis.